Brief description not available

Chronic wounds affect over 6.5 million people in the United States costing more than $25B annually. 23% of military blast and burn wounds do not close, affecting a military patient's bone, skin, nerves. Moreover, 64% of military trauma have abnormal bone growth into soft tissue. Slow healing of recalcitrant wounds is a known and persistent problem, with incomplete healing, scarring, and abnormal tissue regeneration. Precise control of wound healing depends on physician's evaluation, experience. Physicians generally provide conditions and time for body to either heal itself, or to accept and heal around direct transplantations, and their practice relies a lot on passive recovery. While newer static approaches have demonstrated enhanced growth of non-regenerative tissue, they do not adapt to the changing state of wound, thus resulting in limited efficacy. One potential unmet clinical need is related to todays rigid form factors. Modern delivery systems lack adequate conformal capability to adapt to complex surfaces (e.g., feet, joints, curved surfaces) where chronic wounds frequently occur. If modern devices have semi-flexible printed circuit boards they have not maintained consistent wound contact during patient movement, leading to variable delivery rates and reduced efficacy.

Chronic wounds affect over 6.5 million people in the United States costing more than $25B annually. 23% of military blast and burn wounds do not close, affecting a military patient's bone, skin, nerves. Moreover, 64% of military trauma have abnormal bone growth into soft tissue. Slow healing of recalcitrant wounds is a known and persistent problem, with incomplete healing, scarring, and abnormal tissue regeneration. Precise control of wound healing depends on physician's evaluation, experience. Physicians generally provide conditions and time for body to either heal itself, or to accept and heal around direct transplantations, and their practice relies a lot on passive recovery. While newer static approaches have demonstrated enhanced growth of non-regenerative tissue, they do not adapt to the changing state of wound, thus resulting in limited efficacy. Advanced wound healing devices generally lack true portability and home-use capability due to bulk, complexity, and/or power requirements. One potential unmet clinical need is the integration of a portable wearable design with modern and sometimes de novo components e.g., specialized microfluidic channels, reliable iontophoretic actuators, and programmable temporal controls.

A monoclonal antibody that selectively targets the NLRP3 pyrin domain to inhibit inflammasome activation in inflammasome-related diseases.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Researchers at the University of California, Davis have demonstrated that THR-β agonists such as resmetirom, when repurposed, can effectively treat heart failure with preserved ejection fraction (HFpEF), addressing unmet clinical needs.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available